Biomarkers, Clinical Course, and Individual Needs in COPD Patients in Primary Care: The Study Protocol of the Stockholm COPD Inflammation Cohort (SCOPIC)
暂无分享,去创建一个
[1] M. Miravitlles,et al. [Translated article] Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. , 2022, Archivos de bronconeumologia.
[2] A. Lindén,et al. Occupational exposure to particles and increased risk of developing chronic obstructive pulmonary disease (COPD): A population-based cohort study in Stockholm, Sweden. , 2021, Environmental research.
[3] J. Soriano,et al. Spanish COPD Guidelines (GesEPOC) 2021: Updated Pharmacological treatment of stable COPD. , 2021, Archivos de bronconeumologia.
[4] J. Lötvall,et al. Decreased COPD prevalence in Sweden after decades of decrease in smoking , 2020, Respiratory Research.
[5] L. Fairclough,et al. The role of CD8 + T lymphocytes in chronic obstructive pulmonary disease: a systematic review , 2020, Inflammation research : official journal of the European Histamine Research Society ... [et al.].
[6] A. Lindén,et al. Increased MUC1 plus a larger quantity and complex size for MUC5AC in the peripheral airway lumen of long-term tobacco smokers. , 2020, Clinical science.
[7] Min Li,et al. Reduced Serum Concentration of CC16 Is Associated with Severity of Chronic Obstructive Pulmonary Disease and Contributes to the Diagnosis and Assessment of the Disease , 2020, International journal of chronic obstructive pulmonary disease.
[8] A. Nager,et al. COPD patients need more information about self-management: a cross-sectional study in Swedish primary care , 2019, Scandinavian journal of primary health care.
[9] Kamlesh Khunti,et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician , 2018, Advances in Therapy.
[10] S. Wong,et al. Eosinophilia and clinical outcome of chronic obstructive pulmonary disease: a meta-analysis , 2017, Scientific Reports.
[11] G. Ciprandi,et al. Inflammatory biomarkers for asthma endotyping and consequent personalized therapy , 2017, Expert review of clinical immunology.
[12] Laura Fratiglioni,et al. Assessing and Measuring Chronic Multimorbidity in the Older Population: A Proposal for Its Operationalization , 2016, The journals of gerontology. Series A, Biological sciences and medical sciences.
[13] A. Bossios,et al. Interleukin-16-producing NK cells and T-cells in the blood of tobacco smokers with and without COPD , 2016, International journal of chronic obstructive pulmonary disease.
[14] A. Lindén,et al. Systemic signs of neutrophil mobilization during clinically stable periods and during exacerbations in smokers with obstructive pulmonary disease , 2015, International journal of chronic obstructive pulmonary disease.
[15] G. Wesseling,et al. Do We Need Tailored Smoking Cessation Interventions for Smokers with COPD? A Comparative Study of Smokers with and without COPD Regarding Factors Associated with Tobacco Smoking , 2015, Respiration.
[16] A. Lindén,et al. Systemic cytokine signaling via IL-17 in smokers with obstructive pulmonary disease: a link to bacterial colonization? , 2015, International journal of chronic obstructive pulmonary disease.
[17] K. Larsson,et al. Improvement in COPD management by access to asthma/COPD clinics in primary care: data from the observational PATHOS study. , 2014, Respiratory medicine.
[18] N. Zwar,et al. Patients’ perspectives on the impact of a new COPD diagnosis in the face of multimorbidity: a qualitative study , 2014, npj Primary Care Respiratory Medicine.
[19] Å. Wheelock,et al. Distribution of T-cell subsets in BAL fluid of patients with mild to moderate COPD depends on current smoking status and not airway obstruction. , 2014, Chest.
[20] P. Frith,et al. Self management for patients with chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.
[21] S. Kon,et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. , 2014, The Lancet. Respiratory medicine.
[22] L. Törnkvist,et al. The process of trying to quit smoking from the perspective of patients with chronic obstructive pulmonary disease. , 2012, Scandinavian journal of caring sciences.
[23] B. Fischer,et al. Pathogenic triad in COPD: oxidative stress, protease–antiprotease imbalance, and inflammation , 2011, International journal of chronic obstructive pulmonary disease.
[24] A. Bossios,et al. Effects of tobacco smoke on IL-16 in CD8+ cells from human airways and blood: a key role for oxygen free radicals? , 2011, American journal of physiology. Lung cellular and molecular physiology.
[25] Edwin K Silverman,et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. , 2010, American journal of respiratory and critical care medicine.
[26] T. Louis,et al. Eosinophil and T cell markers predict functional decline in COPD patients , 2009, Respiratory research.
[27] P. Jones,et al. Development and first validation of the COPD Assessment Test , 2009, European Respiratory Journal.
[28] S. Duncan,et al. Role of T-lymphocytes and pro-inflammatory mediators in the pathogenesis of chronic obstructive pulmonary disease , 2008, International journal of chronic obstructive pulmonary disease.
[29] M. Hyland,et al. Educational impact of pulmonary rehabilitation: Lung Information Needs Questionnaire. , 2008, Respiratory medicine.
[30] Helvi Kyngäs,et al. The qualitative content analysis process. , 2008, Journal of advanced nursing.
[31] S. Hodge,et al. Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects , 2007, Clinical and experimental immunology.
[32] N. McElvaney,et al. The role of secretory leucoprotease inhibitor in the resolution of inflammatory responses. , 2007, Biochemical Society transactions.
[33] R. Perng,et al. Inhaled Fluticasone and Salmeterol Suppress Eosinophilic Airway Inflammation in Chronic Obstructive Pulmonary Disease: Relations with Lung Function and Bronchodilator Reversibility , 2006, Lung.
[34] K Larsson,et al. Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. , 2003, Respiratory medicine.
[35] W. Bailey,et al. Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution , 2023, Medical science monitor : international medical journal of experimental and clinical research.
[36] Bernard,et al. Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[37] C. Steiner,et al. Comorbidity measures for use with administrative data. , 1998, Medical care.
[38] A. Bernard,et al. Decrease of serum Clara cell protein in smokers , 1992, The Lancet.
[39] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[40] J. Fawcett,et al. The metaparadigm of nursing: present status and future refinements. , 1984, Image--the journal of nursing scholarship.